SEL-201 / Roche, Cartesian Therapeutics - LARVOL DELTA

MNK1 signaling induces an ANGPTL4-mediated gene signature to drive melanoma progression. (PubMed, Oncogene) - "Among the MNK1-upregulated genes, we identify Angiopoietin-like 4 (ANGPTL4), which in turn promotes an invasive phenotype via its ability to induce the expression of matrix metalloproteinases (MMPs). Using a pharmacologic inhibitor of MNK1/2, SEL201, we demonstrate that BRAF-mutated cutaneous melanoma cells are reliant on MNK1/2 for invasion and lung metastasis."

Journal • BRAF • GS

Inhibitory effects of SEL201 in acute myeloid leukemia. (PubMed, Oncotarget) - "Combination of SEL201 with 5'-azacytidine or rapamycin results in synergistic inhibition of AML cell growth. Collectively, these results suggest that SEL201 has significant antileukemic activity and further underscore the relevance of the MNK pathway in leukemogenesis."

Journal • EIF4E

MNK1/NODAL signaling promotes invasive progression of breast ductal carcinoma in situ. (PubMed, Cancer Res) - "The MNK1/2 inhibitor SEL201 blocked DCIS progression to invasive disease in vivo...In clinical samples, IDC and DCIS with microinvasion expressed higher levels of phospho-MNK1 and NODAL versus low grade (invasion-free) DCIS. Cumulatively, our data support further development of MNK1 inhibitors as therapeutics for preventing invasive disease."

Journal